BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27943422)

  • 1. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Eur J Haematol; 2017 Apr; 98(4):337-347. PubMed ID: 27943422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
    Adams HJA; Kwee TC
    Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
    Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
    Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.
    Adams HJ; Nievelstein RA; Kwee TC
    J Comput Assist Tomogr; 2017 Jan; 41(1):98-103. PubMed ID: 27560022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T; Nihashi T; Hotta T; Nagai H
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
    Adams HJA; Nievelstein RAJ; Kwee TC
    Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
    Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
    Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
    Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
    Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
    Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
    Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of fluorine-18 fluorodeoxyglucose PET in prognosis evaluation for stem cell transplantation of lymphoma: a systematic review and meta-analysis.
    Wang C; Li P; Wu S; Lu J; Liu Q; Luo H; Song S
    Nucl Med Commun; 2016 Apr; 37(4):338-47. PubMed ID: 26741290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.